We have recently demonstrated that activation of Akt1 in breast tumor cells in vitro, leads to inactivation of FOXO1 and a decrease in response or resistance to trastuzumab-induced growth inhibition in HER2 overexpressing breast cancer cells [12]. This evidence concerns the gene AKT1 and breast cancer.